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Abstract
Background
Chronic pain is common in multimorbid patients. However, little is known about the implica-
tions of chronic pain and analgesic treatment on multimorbid patients. This study aimed to
assess chronic pain therapy with regard to the interaction potential in a sample of inpatients
with multiple chronic conditions.
Methods and Findings
We conducted a retrospective study with all multimorbid inpatients aged18 years admitted
to the Department of Internal Medicine of University Hospital Zurich in 2011 (n = 1,039
patients). Data were extracted from the electronic health records and reviewed. We identi-
fied 433 hospitalizations of patients with chronic pain and analyzed their combinations of
chronic conditions (multimorbidity). We then classified all analgesic prescriptions according to
the World Health Organization (WHO) analgesic ladder. Furthermore, we used a Swiss drug-
drug interactions knowledge base to identify potential interactions between opioids and other
drug classes, in particular coanalgesics and other concomitant drugs. Chronic pain was pres-
ent in 38% of patients with multimorbidity. On average, patients with chronic pain were aged
65.7 years and had a mean number of 6.6 diagnoses. Hypertension was the most common
chronic condition. Chronic back pain was the most common painful condition. Almost 90% of
patients were exposed to polypharmacotherapy. Of the chronic pain patients, 71.1% received
opioids for moderate to severe pain, 43.4% received coanalgesics. We identified 3,186 poten-
tial drug-drug interactions, with 17% classified between analgesics (without coanalgesics).
Conclusions
Analgesic drugs-related DDIs, in particular opioids, in multimorbid patients are often complex
and difficult to assess by using DDI knowledge bases alone. Drug-multimorbidity interactions
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are not sufficiently investigated and understood. Today, the scientific literature is scarce for
chronic pain in combination with multiple coexisting medical conditions and medication regi-
mens. Our work may provide useful information to enable further investigations in multimor-
bidity research within the scope of potential interactions and chronic pain.
Introduction
Pain is a medical condition listed among the most common diseases worldwide. The most
common causes of chronic pain relate to musculoskeletal disorders [1]. Prevalence estimates
for musculoskeletal pain in elderly patients vary widely, from 32.9% to 60% in Europe [2, 3].
Typically, many people with musculoskeletal pain are multimorbid and receive polypharma-
cotherapy [4, 5]. Previous, studies on multimorbidity have reported chronic pain diagnoses
and treatments as an outcome of only secondary interest—for instance, as a medical condition
co-occurring with somatic and mental health disorders [6–9]. Opioids are a mainstay of
chronic pain treatment according to the World Health Organization (WHO) three-step anal-
gesic ladder, which was developed in the mid-1980s as a scheme for patients with cancer pain
[10]. Meanwhile, opioids have become increasingly popular as a treatment option for patients
with chronic non-cancer pain [11, 12], and the range of applications of the WHO analgesic
ladder has been extended accordingly.
The WHO scheme also introduced the term “adjuvant drugs”; originally, a small number of
drugs (e.g., anxiolytics) was described as adjuvants, to enhance the analgesic “three-step”
sequence from non-opioids, to weak opioids, and finally to strong opioids [13]. Later, the
scope of these drugs was extended [14]. Key recommendations for adjuvant drugs, as
described in the WHO analgesic ladder approach, were to treat adverse effects of analgesics
(e.g., antiemetics or laxatives), to enhance pain relief (e.g., corticosteroids in spinal nerve com-
pression), and to treat concomitant psychological comorbidities (e.g., psychotropic drugs).
Today, adjuvant or coanalgesic drugs have become established in the treatment of cancer
pain and non-cancer pain. As a consequence, the broad range of alternative analgesic strategies
increases the risk of polypharmacotherapy. From this perspective, chronic pain therapy in
patients with multiple chronic conditions can be challenging [15]. Little is known, on the one
hand, about the clinical impact of opioids and potential adverse drug-drug interactions (DDIs)
in multimorbid patients [16], and, on the other hand, about the clinical impact of drug-disease
interactions in combination with coanalgesics in patients with chronic pain and multimorbidity.
The primary aim of this study was to assess drugs used to treat pain in multimorbid patients
at a tertiary teaching hospital. The secondary aim was to examine the potential of DDIs by
using an electronic DDI knowledge base.
We undertook the following steps:
1. We explored the current literature on common chronic conditions and their potential to
modify chronic pain.
2. We identified and characterized the target population from patients’ electronic medical
chart reviews;
3. We examined and described analgesic prescriptions corresponding to the WHO analgesic
pain ladder;
4. We examined and described coanalgesic and concomitant drugs of the target population;
5. We reviewed the potential for DDIs; and
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Material and Methods
Data Collection
The University Hospital Zurich is a tertiary teaching hospital with 850 beds and about 38,000
inpatient admissions per year. We used a retrospective data set of all multimorbid inpatients
admitted to the Department of Internal Medicine in 2011 (n = 1,139 hospitalizations). We
included all adult inpatients discharged between January 1 and December 31, 2011, aged 18
years and older, and with more than one chronic medical condition. Patients in a methadone
program, pregnant women, and palliative care patients were excluded. This study was con-
ducted in accordance with the Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) guidelines [17].
Data were extracted from the hospital’s electronic health records by the hospital’s Research
Center for Medical Informatics. The following variables were extracted and transferred to a
spreadsheet (Microsoft Excel1 2010, www.microsoft.com): date of admission, gender, age
(years), length of hospital stay (days), all chronic pain diagnoses, all diagnoses of other chronic
conditions, and all medications prescribed during hospitalization. Two physicians reviewed
each case with regard to the inclusion and exclusion criteria and completed a list of diagnoses,
using the patient’s care and discharge report. Patients were categorized as ‘with’ or ‘without’ a
painful chronic condition. The diagnoses identified were marked as active if the painful condi-
tion required the prescription of analgesics during the patient’s hospital stay. In addition, all
analgesic prescriptions were assessed in accordance with the WHO analgesic ladder approach
[14]. All chronic conditions were transformed from the ICD-10 to ICPC-2 standard based on
the list of chronic conditions provided by O’Halloran et al. [18]. Some ICPC-2 codes were
grouped together—for example, the diagnosis of cancer (including solid malignant tumors of
different types). All relevant patient charts were individually reviewed and completed by mem-
bers of the research team. Unclear information about a patient record was reviewed by the
study group and agreed on before coding. In a first step we looked at our patient population
with regard to multimorbidity and the most frequent combinations of single diseases (triplets),
including the drugs prescribed during their hospital stay. In a second step, we classified all pre-
scribed analgesics according to the single steps of the WHO analgesic ladder.
Drug-drug interaction knowledge base. Potential interactions between opioids, coanal-
gesics and other drug classes were identified using the Swiss drug-drug interaction knowledge
base galdat/hospINDEX1 (distributed by e-mediat AG, Berne, Switzerland; derived from
ABDATA Pharma-Daten, Eschborn, Germany), The knowledge base is used at the University
Hospital Zurich (at present hospINDEX 2016–05)[19]. This knowledge base categorizes DDIs
by severity from level 1 (contraindicated) to level 6 (no action required), according to the
ORCA criteria (operational classification of drug interactions, with a focus on clinically rele-
vant interacting drug pairs) [20]. The treatment recommendations presented are collected
from clinical practice guidelines, pharmaceutical drug information, or case reports, and they
include country-specific information. The frequency of potential DDIs was calculated as the
total number of overlapping drug orders identified as interacting according to the knowledge
base. In detail, potential DDIs were described separately for opioid-related DDIs and for coa-
nalgesic or concomitant drugs.
Definitions
Multimorbidity. Multimorbidity was defined as the co-occurrence of two or more
chronic medical conditions [21, 22]. Chronic conditions were defined following O’Halloran
Chronic Pain, Opioids and Multimorbidity
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et al. [18], based on the International Classification of Primary Care, second edition (ICPC-2)
disease classification system.
Chronic pain. The International Association for the Study of Pain defined chronic pain as
“pain that persists beyond the normal time of healing” [23]. We defined the persistence of pain
for more than three months as chronic. We defined DDIs as a modification of the effect of a
drug or as an adverse effect resulting from concomitant administration of one or more other
drugs. We refer to potential DDIs only, as actual adverse drug events were not considered in
this study. Drug-disease interactions were defined as a modification in the endogenous regula-
tory system, either in an already pathologically altered or in a hitherto unaffected regulatory
system.
Adjuvants/coanalgesics. The terms ‘adjuvant drugs,’ ‘adjuvants,’ ‘adjuvant analgesics’
[24–26], ‘coanalgesics,’ or ‘concomitant medication’ in persistent opioid use [27, 28] have been
used simultaneously and interchangeably over the past two decades. To date, there is still no
consensus in the literature on how to classify the growing number of such agents [29]. Criteria
for a meaningful classification have been recommended by Lussier et al. [30]; however, these
are applied mainly in the context of cancer pain: adjuvant analgesics were defined as drugs
with a primary indication other than pain but having analgesic properties in some painful con-
ditions. From this perspective, adjuvants are potentially beneficial as analgesics, and as a result,
the categorization is based on how they are used in clinical practice. Coanalgesics have since
become established for the treatment of cancer pain as well as non-cancer pain.
Chronic Pain Treatment and the WHO Analgesic Ladder
Patients’ pain medications were specified by trade name, using the Anatomical Therapeutic
Chemical Classification System code; the duration (in days) of the prescription was also deter-
mined. Analgesic prescriptions were assigned to the steps of the WHO analgesic ladder [14]:
non-opioid analgesics (step I), weak opioids (step II), and strong opioids (step III). This classi-
fication of analgesics is conventionally based on their activity at opioid receptors as either non-
opioid or opioid. To characterize all relevant groups with an analgesic effect we used three
terms to distinguish between these groups: (1) analgesics–drugs for pain relief based on the
WHO analgesic ladder (non-opioids, weak and strong opioids) – i.e., paracetamol (acetamino-
phen) as a non-opioid; (2) coanalgesics–drugs that are distinctly prescribed in the specific con-
text of pain relief; i.e., pregabalin approved for the treatment of neuropathic pain; and (3)
concomitant medication–concurrent use of any drugs that are given in the context of multi-
morbidity. In some cases nevertheless they may have a modifying effect on pain – i.e., antide-
pressants for coexisting depression.
Data Management and Statistical Analysis
For the statistical analyses, we used Stata1 statistical software (Version 13, Stata Corporation,
College Station, TX; www.stata.com). Continuous data were presented as means with standard
deviations, categorical data as counts and proportions. We used t-tests to compare continuous
data and chi square tests to compare categorical data. The significance level was set at 0.05.
Ethics Approval
Ethics approval for this study was obtained from the Research Ethics Committee of the Canton
of Zurich, KEK-ZH-No. 2012–0237, which waived the requirement for obtaining informed
consent for this retrospective review of electronic medical records. All patient records and
information were anonymized and de-identified before the analysis.
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Results
Study Population and Diagnoses
The prevalence of chronic pain found among the 1039 multimorbid inpatients was 38%
(n = 393). On average, these patients were 66 years old, with no significant difference in age
between multimorbid patients with and without chronic pain (p = 0.318; Table 1). Multimor-
bid patients with chronic pain (CP) had significantly more chronic diagnoses (with a mean of
6.6 chronic diagnoses, with 4.4 different organ systems involved) compared with multimorbid
patients without chronic pain (mean of 5.0 conditions and 3.1 organ systems involved)
(p< 0.00005). Moreover, patients with CP had significantly longer hospital stays than multi-
morbid patients without CP (15.5 vs. 12.5 days, p = 0.0007).
Hypertension, chronic kidney disease, and diabetes were the most frequent single chronic
conditions in both groups, with prevalence estimates for the group with CP of 58.7% for hyper-
tension, 29.1% for chronic kidney disease, and 23.1% for diabetes (data not shown). When
only patients with chronic pain diagnoses were considered (Table 2), the most common triple
Table 1. Sociodemographic characteristics of the study population (n = 1039): Comparison of multimorbid patients with and without chronic pain
in a population of inpatients in a department of internal medicine in a tertiary care hospital.
Patients Multimorbid patients with chronic pain
(n = 393)
Multimorbid patients without chronic pain
(n = 646)
p-value
Gender, n (%) p = 0.029
Male 202 (51.4) 377 (58.4)
Female 191 (48.6) 269 (41.6)
Mean age, in years (SDa) 65.7 (15.9) 66.7 (15.5) p = 0.318
Hospitalization p = 0.710
Single hospitalization in 2011 (%) 358 (91.1) 584 (90.4)
Multiple hospitalization in 2011 (%) 35 (8.9) 62 (9.6)
Cases Multimorbid patients with chronic pain
(n = 433)
Multimorbid patients without chronic pain
(n = 706)
p-value
Mean number of chronic conditions
(SD)
6.6 (2.9) 5.01 (2.4) p < 0.00005
Mean days of stay in hospital (SD) 15.7 (19.1) 12.5 (11.6) p < 0.0007
a SD = Standard deviation.
doi:10.1371/journal.pone.0168987.t001
Table 2. Top 10 chronic pain conditions/chronic conditions associated with chronic pain respectively
in a population of inpatients at a department of internal medicine in a tertiary care hospital (n = 433
hospitalizations). Multiple counts were allowed.
Most frequent chronic pain diagnoses Prevalence in %
Chronic back pain 38.8
Osteoarthrosis (joint disorders) 17.6
Cancer 16.6
Rheumatoid/seropositive arthritis 8.1
Musculoskeletal diseases, othera 6.9
Cholecystitis/cholelithiasis 6
Osteoporosis 5.3
Chronic enteritis/ulcerative colitis 4.8
Gout 4.2
Neurological diseases 3.9
a This diagnosis includes specific arthropathies, e.g., crystal- related arthropathies.
doi:10.1371/journal.pone.0168987.t002
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combination was hypertension, chronic back pain, and chronic kidney disease (Table 3). Fur-
ther, 15.3% of the patients with CP had depressive disorders, which is almost twice as many as
the multimorbid patients without CP who had depressive disorders (p< 0.00005). Logistic
regression showed that this difference in the prevalence of depression was not explained by
either different numbers of chronic conditions or differences in the duration of hospitaliza-
tion. After adjustment, the difference in the probability of depression between pain and non-
pain patients remained significant (p = 0.008).
Of all patients with CP, 60% had one, 27% had two, and 13% had three or more pain diag-
noses, respectively. The most common chronic pain diagnosis was chronic back pain (38.6%;
Table 2), followed by chronic pain diagnoses, such as osteoarthrosis (17.6%), and painful con-
ditions subsequent to cancer (16.6%). Of the 10 most frequent pain diagnoses, seven were
related to chronic musculoskeletal diseases.
Pain Treatment and WHO Analgesic Ladder
The most frequent mode of prescription in terms of assignment to the WHO analgesic ladder
was a combination of step I analgesics (non-opioids) with step III analgesics (strong opioids)
in 35% of all CP hospitalizations with no step II analgesics (weak opioids). The second most
frequent mode was a prescription of step I analgesics only (29%), followed by (third) concur-
rent prescription of all three steps (19%). Step I analgesics were prescribed to 98.6% of all inpa-
tients with CP, with paracetamol (acetaminophen) or metamizole (novaminsulfone) the most
often prescribed (Table 4). In total, 71.1% of these CP patients received opioids, in different
combinations, for moderate to severe pain. The most frequent combination with a longer
(more than a day) simultaneous prescription of weak and strong opioids was tramadol and
morphine. All of these 58 prescriptions were additionally complemented with step I analgesics.
In 21 of these 58 simultaneous opioid medications, an upward change took place (stronger
medications were required over time), and consequently only strong opioids were prescribed.
Coanalgesic and Concomitant Drugs
Overall, 43.4% (188) of all patients with chronic pain received drugs prescribed as coanalgesics.
In addition, quite a number of these patients received drugs that were not primarily prescribed
as analgesics but that have analgesic properties in some painful conditions (concomitant
drugs) (Table 5).
Table 3. The most common triplets of chronic conditions including chronic pain diagnoses in a population of inpatients at a tertiary department
of internal medicine (n = 433 hospitalizations).
Chronic conditions Prevalence in %
Chronic back pain Hypertension Chronic kidney disease 9.9
Chronic back pain Hypertension Ischemic heart diseases 7.9
Chronic back pain Hypertension Diabetes 7.2
Osteoarthrosis Hypertension Chronic kidney disease 7.2
Chronic back pain Hypertension Osteoarthrosis 6.5
Chronic back pain Hypertension Peripheral neuritis/neuropathy 6.0
Chronic back pain Hypertension Atrial fibrillation/flutter 5.5
Chronic back pain Hypertension Arteriosclerosis 5.3
Osteoarthrosis Hypertension Diabetes 5.1
Chronic back pain Ischemic heart diseases Chronic kidney disease 5.1
doi:10.1371/journal.pone.0168987.t003
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Antidepressants were assigned to both categories (coanalgesic and concomitant drugs).
Potentially, antidepressants could be considered for the treatment of chronic pain and for the
treatment of depressive disorders (66 cases). Alpha-2 adrenergic agonists, antidepressants, and
corticosteroids have been categorized as multipurpose analgesics (multipurpose drugs have a
various range of indications). Almost all patients received laxatives and antiemetic drugs. Most
laxative agents were those that predominantly soften the stool (liquid paraffin). In addition to
prokinetic agents/anti-emetics (domperidone and metoclopramide), other drugs –for exam-
ple, corticosteroids –may enhance an antiemetic strategy. Pregabalin has been identified as a
coanalgesic in the management of neuropathic pain (32 cases). All other antiepileptic drugs
should be considered in patients with epilepsy or pain relief.
Drug-Drug Interactions
With an average mean of 10.4 medications (SD = 4.9) prescribed per inpatient hospitalization
with chronic pain, the amount of polypharmacotherapy (five or more drugs) was high, at 89%
of all cases. We identified 3,186 potential DDIs (overlapping drug orders of drug pairs listed as
interacting in the drug-drug interaction knowledge base), with 551 (17%) potential interac-
tions between analgesics (without coanalgesics); 175 (5.5%) were with opioids. None of the
interactions were classified as severity level 1 interactions (“contraindicated”). The DDIs
knowledge base classified most potential interactions with opioids in our inpatients as severity
level 3 (“monitoring or adaption required”); the only exception were the DDIs between bupre-
norphine and opioid agonists, as severity level 2 (“contraindicated as a precaution”) (Table 6).
In a later version of this DDIs knowledge base, hospINDEX (2016–05), the interaction with
buprenorphine is classified as severity level 3.
Table 7 shows an overview of DDIs between analgesics, coanalgesics, concomitant drugs,
and other drugs (e.g., antihypertensive drugs) prescribed to the study population of multimor-
bid inpatients with CP. All potential DDIs listed here were identified in the data set accord-
ingly. This table is based on the recommendations in the drug-drug interactions knowledge
base used in this study (galdat/hospINDEX1).
Table 4. Drug prescriptions in multimorbid patients with chronic pain corresponding to the classification by the WHO analgesic ladder.
WHO analgesic
ladder
No. of cases (n = 433) No. of cases in % Most frequently prescribed analgesics
Step I only 125 28.9 paracetamol, metamizole, NSAIDsa
Step II only 2 0.5 tramadol*
Step III only 4 0.9 morphine, oxycodone, fentanyl transdermal
Step I + II 66 15.2 step I: paracetamol, metamizole
step II: tramadol*
Step I + III 152 35.1 step I: paracetamol, metamizole
step III: morphine, oxycodone, fentanyl transdermal, pethidine, oxycodone-
naloxone
Step I + II + III b 84 19.4 step I: paracetamol, metamizole
step II: tramadol*
step III: morphine
a NSAIDs = nonsteroidal anti-inflammatory drugs.
b 58 cases with an overlap ( 24 hours) of opioids (step II and step III).
* Total: 147 cases including tramadol prescriptions.
doi:10.1371/journal.pone.0168987.t004
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Table 5. Classification of coanalgesics and concomitant drugs.
Drug class Coanal-gesics Con-comitant drugs Number of cases Reason for classification
Alpha-2 adrenergic agonists 4 multipurpose
Clonidine hypertension
Antidepressants multipurpose
Mirtazapine 38 66 cases with diagnosis of depression
Citalopram 24 84 cases without diagnosis of depression
Trazodone 17
Escitalopram 15
Venlafaxine 15
Amitriptyline 13
Trimipramine 12
Sertraline 11
Duloxetine 8
Fluoxetine 5
Olanzapine 3
Clomipramine 2
Paroxetine 2
Mianserin 2
St. John’s wort preparations 2
Opipramol 1
Antiemetic, prokinetic nausea, vomiting, prokinetic
Domperidone 367
Metoclopramide 145
Antiepileptic drugs
Phenytoin 1 epilepsy
Carbamazepine 7 epilepsy; painful trigeminal neuropathy
Valproate 3 epilepsy
Pregabalin 32 peripheral neuropathy
Gabapentin 8 epilepsy; peripheral neuropathy
Topiramate 3 epilepsy; migraine
Corticosteroids multipurpose
Prednisone 104 antiinflammatory, relief of different symptoms (e.g., pain, nausea, fatigue)
Dexamethasone 25
Methylprednisolone 16
Hydrocortisone 4
Baclofen 3 spasticity and pain
Benzodiazepines nervousness, sleep disturbance, anxiety disorders
Lorazepam 147
Oxazepam 40
Bromazepam 8
Butylscopolamine 35 pain from bowel obstruction
General Anesthetic 2
Ketamine
Local Anesthetic
Lidocaine 6
Ropivacaine 3
Capsaicin (topical) 2
Magnesium sulfate hypomagnesemia, constipation, spasms
Magnesium aspartate 84
Magnesium citrate 2
Muscle relaxants exacerbation or acute musculoskeletal pain
Tizanidine 11
Tolperisone 1
Laxatives prophylaxis and management of constipation
Liquid paraffin, combinations 382 (e.g., opioid induced)
Macrogol, combinations 119
Lactulose 35
Sodium picosulfate 31
(Continued)
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Table 5. (Continued)
Drug class Coanal-gesics Con-comitant drugs Number of cases Reason for classification
Senna glycosides 18
Glycerol 10
Bisacodyl 9
Ispaghula (psyllium seeds) 7
Lactitol 2
Sodium phosphate 1
Neuroleptic drugs management of delirium, psychosis, nausea, emesis
Haloperidol 20
Quetiapine 6
Risperidon 4
Chlorpromazine 3
Olanzapine 3
Paliperidone 1
Osteoclast inhibitors prevent skeletal-related events, may improve pain
Bisphosphonate Derivative (neuropathic or malignant bone pain)
Alendronic acid 9
Risedronic acid 1
Calcitonin 9
doi:10.1371/journal.pone.0168987.t005
Table 6. Potential opioid related drug-drug interactions (DDIs) in multimorbid patients with chronic pain (n = 433), identified by using the galdat/
hospINDEX® database. Multiple counts were allowed.
Medication class 1 (identified drugs) * Medication class 2
(identified drugs) *
Potential DDI
(n)
Severity level of
inter-actionb
Possible drug interaction
Antidepressants: SSRIs, SNRIs Opioids 57 5 Provocation of a serotonin
syndrome
(trazodone, escitalopram, venlafaxine, citalopram, duloxetine,
sertraline, fluoxetine, and paroxetine)
(oxycodone, tramadol, and
pethidine)
Anticoagulation drugs Opioids 32 3 Increased effect of anticoagulation
drugs
(phenprocoumon) (tramadol) Risk of bleeding
Azole antifungal agents Opioids 30 3 Increased analgesic effect
(fluconazole, itraconazole, and voriconazole) (oxycodone, tramadol, and
fentanyl)
(increased drug toxicity or
prolonged adverse events)
CYP 3A4 inducersa Opioids 25 3 Decreased analgesic effect
(rifampicin, carbamazepine, St. John’s wort preparations
[Hypericum perforatum], phenobarbital, and phenytoin)
(oxycodone, fentanyl, and
tramadol)
Benzodiazepine Opioids 10 3 Increased risk of CNS depressant
effects c
(lorazepam, oxazepam, bromazepam) (buprenorphine) (hypotension, respiratory
depression, or sedation)
Opioid partial agonist drugs Opioids 8 2 Decreased analgesic effect
(buprenorphine) (morphine, oxycodone, and
tramadol)
Risk of withdrawal syndrome
CYP 3A4 inhibitors Opioids 7 3 Increased effect of fentanyl
derivatives
(verapamil, clarithromycin, amiodarone) (fentanyl)
Antidepressants, tricylcic Opioids 6 3 Increased risk of seizures
(trimipramine, amitriptyline, opipramol) (tramadol)
DDIs with buprenorphin and opioid agonists: The level 2 of severity recommended by Galdat is controversially discussed in the literature [31].
a CYP = cytochrome P450.
*based on their frequency.
b Severity according to galdat/hospINDEX®: 1: ‘contraindicated’, 2:‘contraindicated as a precaution‘, 3: ‘monitoring or adaptation required’, 4: ‘monitoring or
adaption in case of risk factors’, 5: ‘monitoring as a precaution’, 6: ‘no action required‘.
c CNS = central nervous system.
doi:10.1371/journal.pone.0168987.t006
Chronic Pain, Opioids and Multimorbidity
PLOS ONE | DOI:10.1371/journal.pone.0168987 January 3, 2017 9 / 18
Discussion
This study provides a general overview of the most common chronic pain diagnoses and com-
binations of chronic diseases (triplets) and the prescribed medications, respectively, in the
multimorbid population under study. We discuss possible consequences of these data in
regard to the impact of pain treatment on different multiple disease combinations found and
vice versa. Furthermore, we discuss potential DDIs related to pain treatment with a focus on
opioids and some selected coanalgesic or concomitant drugs.
In our study, 38% of all multimorbid inpatients had chronic pain. On average, these CP
patients were 65.7 years old, had 6.6 chronic diagnoses, and were exposed to a high degree of
polypharmacotherapy (10.4 drugs). The most common chronic pain diagnoses were musculo-
skeletal diseases (see Table 2). The most common triple disease combination was hypertension,
Table 7. Overview of the relevant drug interaction potential of analgesics (categorized into analgesics, coanalgesics, and concomitant drugs),
identified by galdat/hospINDEX® database in the sample of chronic pain patients (n = 433). Antidepressants are included here as coanalgesics.
Non-opioids Opioids Coanalgesics
Overview of DDIs in
multimorbid
chronic pain
patients
NSAIDs Paracetamol Tramadol Oxycodone Pethidine Buprenorphine Antidepressants,
tricyclic
SSRIs,
SNRIs
Local
anesthetics
(lidocaine)
Osteoclast inhibitors
(bisphosphonates,
calcitonin)
Anticholinergic
drugs (e.g.
scopolamine)
List of interacting
drugs as
recommended by
knowledge base*
Vitamin K
antagonists
(phenprocoumon)
3 4 3 5 5
Antidepressants,
tricylcic
3 3 3
Benzodiazepines 3
Antiepileptic drug
(phenytoin)
Antiepileptic drug
(valproate)
Buprenorphine
SSRIs, SNRIs 3 3 3 3 3
Beta blocker
(metoprolol)
4 5 5
Magnesium salts 3
Neuroleptic drugs:
among others
haloperidol
3 3 3
Serotinergic receptor
agonists
5
Diuretics (e.g loop
diuretic)
4
Antidiabetics: among
others metformin
5
Cardiac glycoside
Dopamine receptor
agonists: e.g.
levodopa
Corticosteroids,
systemic
3
Antiplatelet agents:
among others
acetylsalicylic acid
3
Angiotensin-
converting enzyme
inhibitors
4
Antifolates 3
Osteoclast inhibitors:
bisphosphonates,
calcitonin
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chronic kidney disease, and chronic back pain (see Table 3). Opioids were prescribed in more
than two thirds of CP patients for moderate to severe pain. Coanalgesic drugs were prescribed
Concomitant drugs
Corticosteroids,
systemic
Alpha-2
adrenergic
agonists
Neuroleptic
drugs (e.g.
haloperidol)
Antiepileptic
drug
(phenytoin)
Antiepileptic
drug
(carbamazepine)
Antiepileptic
drug
(valproate)
Anticonvulsant
drug
(topiramate)
Benzodia-
zepines
Antiemetics,
prokinetics
(domperidone)
Antiemtics,
prokinetics
(metoclopramide)
Magnesium
salts
Laxatives
5 5
3 3 3
5 3
5
3 3
3
3 3 3
3
3 3
5 5
3
5 4
5
3 3
3
SSRI, SNRIs: escitalopram, citalopram, sertraline, venlafaxine, duloxetine, fluoxetine, paroxetine.
Antidepressants, tricylcic: trimipramine, amitriptyline, clomipramine, mianserin.
Neuroleptic drugs: pipamperone, thiethylperazine, risperidon, chlorpromazine, quetiapine.
Benzodiazepines: lorazepam, oxazepam, bromazepam.
Pharmacokinetics: A range of drugs prescribed for our inpatients may be affected by induction or inhibition of mainly CYP3A4. These drugs are shown as
examples in Table 6, with a focus on opioids.
* Severity according to galdat/hospINDEX® 1: ‘contraindicated’, 2:‘contraindicated as a precaution‘, 3: ‘monitoring or adaptation required’, 4: ‘monitoring or
adaption in case of risk factors’, 5: ‘monitoring as a precaution’, 6: ‘no action required‘.
doi:10.1371/journal.pone.0168987.t007
Table 7. (Continued)
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for 43% of these patients. The DDIs knowledge base classified most DDIs for these multimor-
bid patients with CP as severity level 3 (“monitoring or adaption required”).
According to the WHO analgesic ladder, non-opioids should be combined with opioids,
but opioids should not necessarily be combined with other opioids. Some experts [32, 33] have
recommended omitting the intermediate step of weak opioids completely and using low doses
of strong opioids in combination with non-opioid analgesics instead. They argue in favor of
this adaptation (a modified two-step approach) of the original WHO analgesic ladder mainly
on the basis that it would establish more effective and simple pain therapy, in particular for
patients with cancer. Omitting step II medication is likely to permit using only one single
(strong) opioid, with modification in doses, and titration according to the patient’s individual
pain level. In general, the use of opioids in combination with other opioids seems to be largely
based on empirical evidence and depends on the physician’s clinical experience [34]. Further-
more, new formulations of analgesics have been developed in the past 10 years—for example,
to prevent the most common side effect of opioid-induced constipation. Meanwhile, the co-
administration of oral naloxone together with oxycodone (prolonged release) is a well-known
regimen [35].
Tramadol in combination with other analgesics (in total 147 cases with tramadol prescrip-
tions) was one of the most frequently prescribed analgesics. Tramadol has a specific dual mode
of action relating to its affinities to the opioid receptors (modest affinity with μ-receptor, weak
affinity to δ and κ) and/or the inhibition of the uptake of noradrenaline and serotonin [36].
Accordingly, tramadol may cause less constipation and respiratory depression than other
strong opioids (e.g., morphine) and might therefore be an alternative choice in patients with
multiple chronic conditions before more potent opioid analgesics are used. Tramadol can be
especially useful in older patients who do not tolerate more potent opioids [37].
The common use of NSAIDs has been identified as critical, especially in terms of adverse
drug events in elderly patients [38, 39]. NSAIDs pose three major risks: they may interfere
with blood pressure control, aggravate renal impairment, or cause gastrointestinal bleeding. In
this study, NSAIDs were found to be rarely used (only in 16%), probably to avoid such well-
known interactions. In our study population chronic kidney disease was a common chronic
condition, 29.1%. This may have been another reason for the low prescription rate of NSAIDs.
At different stages of chronic kidney disease some opioids should be used with caution (risk of
accumulation) possibly at reduced and less frequent doses [40]. However, buprenorphine
seems to be a safe choice in patients with chronic kidney disease [40].
To date, the potential interaction risk of metamizole has not been sufficiently addressed in
research [41]. The same is true for the impact of paracetamol on diagnosed hypertension [42].
But there is some evidence that paracetamol may lessen the effect of antihypertensive drugs
[43]. By contrast, corticosteroids can have a particular impact in combination with diabetes,
osteoporosis, and hypertension (e.g. increased blood pressure). Aggravations of diabetes melli-
tus, as a result of corticosteroid intake as an additional risk factor for osteoporosis are well-
documented. Moreover, administering high doses of corticosteroids may trigger neuropsychi-
atric reactions [44], which may lead to an interaction with a coexisting mental health problem
(e.g. psychosis caused by steroids).
In our study, 17% of total potential DDIs were identified as DDIs with analgesic prescrip-
tions by galdat/hospINDEX1. In particular, this knowledge base put the main focus on drugs
involved in the opioid-cytochrome P450 isoenzymes metabolism and multiple drug transport-
ers (e.g., P-glycoprotein). These well-known DDIs are classified as inhibitors, inducers, or sub-
strate accordingly (see Table 6; drugs as inducers/inhibitors). Some specific properties have to
be noted here, in addition to the recommendation of this knowledge base, such as the fact that
St. John’s Wort (SJW) preparations vary greatly and have different effects on CYP3A4
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induction or in the drug transporter systems. SJW medicinal products with hyperforin-low
Hypericum perforatum extracts are usually not considered to be of clinical relevance as induc-
ers [45, 46]. A clinical pharmacokinetic study showed that treatment with rich-hyperforin SJW
extracts decreases the plasma concentration of oxycodone [47].
For most clinical interactions with opioids identified in our study, galdat/hospINDEX1
resulted in the following advice: “monitoring or adaptation required” (severity level 3). Still,
for the use of the knowledge base a daily review of current medications is recommended (e.g.,
correct applications of drugs and dosing), as well as an individual risk assessment to enhance
patient safety. However, the risk of interactions and adverse events may increase with every
additional medical condition and every additional drug prescribed (polypharmacotherapy)
[48, 49]. Table 5 (overview of coanalgesic and concomitant drugs), shows that concomitant
drugs (laxatives, prokinetic/anti-emetics or neuroleptics) contribute to a high amount of poly-
pharmacotherapy in this study. Potential DDIs are typically analyzed as drug-drug interaction
pairs. For multimorbid patients with multiple drug and disease combinations, the analyses of
two-way drug combinations are certainly not sufficient (see Table 7 for an overview of drug-
drug interactions related to opioid prescriptions). For example, antidepressants (concomitant
or even coanalgesic drugs) can imply an additive interaction risk, as these drugs, identified as
having the most frequent DDIs with opioids in this study, have the potential for numerous
drug interactions [50]. Mental disorders, such as depression, are common comorbid condi-
tions in multimorbid patients. It is well known that the prevalence of depression doubles in
patients with pain [51]. SSRIs (selective serotonin reuptake inhibitors) might interfere to vari-
ous degrees with opioids but also with oral anticoagulation drugs (atrial fibrillation had a prev-
alence of 16.2% in this study) or even NSAIDs, resulting in a cumulative risk for adverse
events [52].
Pain management is usually multimodal and in the first instance aims at reducing pain suf-
ficiently and quickly. Beyond the desired effects of opioids, exogenous opioids can affect a
number of the body’s own regulation systems, especially cardiac and vascular regulation [53].
Table 3 shows the most common chronic pain diagnoses and triplets of chronic conditions
in our multimorbid inpatients. Musculoskeletal pain is not only a common chronic condition
in elderly patients in primary care [54] but also an important coexisting condition in medical
inpatients with multimorbidity, as shown by our study results. Overall, hypertension was the
most common condition (57.7%). This was also reported, for multimorbid patients, with simi-
lar prevalence estimates, in a study of the most common disease combinations [55]. Other rela-
tionships may exist between hypertension and pain perception. Some studies suggest that
chronic pain-related opioid changes (e.g., opioid receptor downregulation) such as hypoalgesia
(i.e., decreased sensitivity to pain) are associated with elevated resting blood pressure [56].
These findings raise questions about potential modifying effects of opioids on pain sensitivity
in patients with untreated hypertension or insufficiently lowered blood pressure. Similar con-
siderations apply to other common disease combinations in multimorbid patients with CP,
such as the treatment of diabetes mellitus (23.1% in this study) and its effect on chronic neuro-
pathic pain. Endogenous opioids also have a role in the regulation of blood glucose and hyper-
insulinemia [57], and it is conceivable that exogenous opioids, such as morphine, may affect
this regulation.
Implications for Research
Intensified research is needed on relevant interactions in clinical practice (e.g. pragmatic tri-
als), which simultaneously includes multimorbid patients with polypharmacotherapy receiving
analgesics, coanalgesics, and a substantial number of concomitant drugs. Research of this kind
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is scarce, and precise data on the interplay of interactions and polypharmacotherapy (on all
sorts of modifying effects) are lacking. Furthermore, it is unclear how the interaction potential
changes in the case of polypharmacotherapy and a reduction of drugs (deprescribing) [58]. A
great need for research exists in this setting (e.g., increasing or decreasing drug dosages and
omitting drugs or adding additional drugs, respectively). Reliable knowledge bases should be
enlarged (interface options) with patient-specific static information (e.g., demographics, con-
current diseases) and dynamic information (e.g., lab results, vital signs), as well as relevant
pharmacodynamic and pharmacokinetic aspects of co-medication and the time course of ther-
apy (start, end, maintenance treatment) [59].
The implementation of a comprehensive tool for the assessment of potential DDIs and drug-
disease interactions in multimorbidity, with a multimorbidity score to estimate the severity of
potential interactions, is probably essential for well-structured, evidence-based clinical decision
making. More research is needed to gain insights into harmful and beneficial effects of various
interactions. In the context of this study, future research could shed light on the (positive and
negative) effects of pain management on the body’s regulation systems—for example, in terms
of possible drug-endogenous opioid activity interactions (e.g., exogenous opioids as possible
ligands of the endogenous opioidergic regulation systems). Critically, the present findings indi-
cate that multimorbidity is insufficiently well-managed by exclusively considering and treating
the individual diseases of a patient with multiple chronic conditions. The potential interactions
(DDIs, drug-multimorbidity interactions) have yet to be investigated.
Our study provides the basis for a deeper understanding of important interaction potential
of patients with chronic pain. As a next step, frequent disease- and drug-combinations in mul-
timorbidity should be investigated in pragmatic clinical trials.
Limitations
Our study has several limitations. First, we examined a highly specific study population at a ter-
tiary hospital. Our results are based on a retrospective medical chart review; with potential
underreporting. Second, owing to the retrospective study design, chronic pain diagnoses had to
be taken from medical health records without accompanying self-reports from patients—for
example, by using the Visual Analog Scale for Pain [60, 61]. Third, we used the galdat/hospIN-
DEX1 knowledge base with country-specific information to identify potential DDIs. Fourth,
we analyzed analgesic prescriptions and not medication intake. The interactions with opioids
reported in this study will therefore have to be interpreted as potential medical conflicts and not
as actual adverse events. A particular strength of our study was the use of detailed electronic
health records for each patient, to review and complete the clinical administrative data.
Conclusions
Our study explored retrospective data of multimorbid patients with chronic pain at a tertiary
teaching hospital. To our knowledge this is the first study examining complex treatment situa-
tions in multimorbid patients with chronic pain. The following conclusions can be drawn:
Analgesics and analgesia-related drugs are often prescribed in combination with a large
variety of other drugs, accompanied by a great potential of risks for multimorbid patients.
Analgesic-related DDIs, in particular opioids, in multimorbid patients are often complex and
difficult to assess by using DDI knowledge bases alone. Drug-multimorbidity interactions are
not sufficiently investigated and understood. Currently, the scientific literature is scarce for
chronic pain in combination with multiple coexisting medical conditions and medication regi-
mens. Our work may provide useful information to enable further investigations in multimor-
bidity research within the scope of potential interactions and chronic pain.
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